

**Preferred Drug List (PDL) News:**  
**This issue of the Pharmacy Benefit Updates contains January 1, 2023 changes to the PDL**

Moving to Preferred	
Aimovig® (ereenumab-aooe) #	Avsola® (infliximab-axxq) #
Baqsimi® (glucagon nasal powder)	Carglumic Acid #
Cinacalcet	Clenpiq® Bowel Prep
Donepezil ODT	Epidiolex® (cannabidiol) #
Fensolvi® (leuprolide acetate)	Fexofenadine tabs
Fexofenadine/pseudoephedrine tabs	Inflectra® (infliximab-dyyb) #
Jivi Antihemophilic - Factor (Recombinant)	Loratadine chewable tabs
Methylphenidate CD (IR/ER 30:70)	Mircera® (methoxypolyethylene glycolepoetin beta) #
Myfembree® (relugolix/estradiol/norethindrone) #	Naratriptan tabs
Nicotrol® (nicotine) nasal spray	Ozempic® (semaglutide)
Qelbree® (viloxazine hydrochloride) #	Trulance® (plecanatide)
Varenicline	Xeljanz® XR (tofacitinib) #
Xeljanz® (tofacitinib) #	Xolair® (omalizumab) #
Zegalogue® (dasiglucagon SC injection)	Zolmitriptan tabs
Zolpidem CR	
Moving to Non-Preferred	
Bethkis® (tobramycin) inhalation solution	Esperoct® Antihemophilic - Factor (Recombinant)
Estazolam	Juluca *
Mucinex® ER (guaifenesin)	Qvar® Redihaler (beclomethasone) *
Remicade® (infliximab)	Renflexis® (infliximab-abda)
Retacrit® (epoetin alpha-epbx)	Sensipar® (cinacalcet)
Suprep® Bowel Prep Kit	Udenyca® (pegfilgrastim-cbqv)
Zafemy® (norelgestromin/ethinyl estradiol) patch	Carbaglu® (carglumic acid)

**To review the complete PDL please refer to:**

<https://dvha.vermont.gov/providers/pharmacy/preferred-drug-list-pdl-clinical-criteria>

**Note:**

- \*Indicates that current uses will be grandfathered.
- # Indicates that the drug will require a clinical Prior Authorization